Advanced NanoTherapies, Inc

About

Advanced NanoTherapies, Inc. (ANT) is a clinical-stage medical device company based in Los Gatos, California. Founded in 2018, ANT specializes in nanotechnology-based drug delivery systems aimed at improving treatments for cardiovascular and endovascular conditions. The company focuses on developing innovative medical devices that enhance drug uptake and retention through its Advanced NanoTherapies (A.N.T.) nanoparticle platform. ANT's flagship product is SirPlux Duo, a dual-therapy drug-coated balloon that delivers Sirolimus and Paclitaxel to prevent restenosis and maintain stent-like patency. This next-generation device targets coronary artery disease (CAD) and peripheral artery disease (PAD), utilizing functionalized nanoparticles for sustained drug release. ANT is currently in the Series A - II funding stage, having raised $17.14 million to support its clinical development efforts, including a successful First-In-Human trial for CAD. The company is committed to advancing its nanotechnology-enhanced medical devices for better patient outcomes.